298 related articles for article (PubMed ID: 31685314)
1. Kidney biopsy-based management of maintenance immunosuppression is safe and may ameliorate flare rate in lupus nephritis.
Malvar A; Alberton V; Lococo B; Ferrari M; Delgado P; Nagaraja HN; Rovin BH
Kidney Int; 2020 Jan; 97(1):156-162. PubMed ID: 31685314
[TBL] [Abstract][Full Text] [Related]
2. A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy.
De Rosa M; Azzato F; Toblli JE; De Rosa G; Fuentes F; Nagaraja HN; Nash R; Rovin BH
Kidney Int; 2018 Oct; 94(4):788-794. PubMed ID: 30045812
[TBL] [Abstract][Full Text] [Related]
3. Correlation between the clinical remission and histological remission in repeat biopsy findings of quiescent proliferative lupus nephritis.
Das U; Patel R; Guditi S; Taduri G
Lupus; 2021 May; 30(6):876-883. PubMed ID: 33611965
[TBL] [Abstract][Full Text] [Related]
4. The clinical relevance of repeat renal biopsies in the management of lupus nephritis: a South African experience.
Tannor EK; Bates WD; Moosa MR
Lupus; 2018 Apr; 27(4):525-535. PubMed ID: 28820361
[TBL] [Abstract][Full Text] [Related]
5. Renal flare prediction and prognosis in lupus nephritis Hispanic patients.
Mejía-Vilet JM; Córdova-Sánchez BM; Arreola-Guerra JM; Morales-Buenrostro LE; Uribe-Uribe NO; Correa-Rotter R
Lupus; 2016 Mar; 25(3):315-24. PubMed ID: 26405028
[TBL] [Abstract][Full Text] [Related]
6. Remission of proteinuria indicates good prognosis in patients with diffuse proliferative lupus nephritis.
Koo HS; Kim S; Chin HJ
Lupus; 2016 Jan; 25(1):3-11. PubMed ID: 26159540
[TBL] [Abstract][Full Text] [Related]
7. Kidney Outcomes and Risk Factors for Nephritis (Flare/
Buyon JP; Kim MY; Guerra MM; Lu S; Reeves E; Petri M; Laskin CA; Lockshin MD; Sammaritano LR; Branch DW; Porter TF; Sawitzke A; Merrill JT; Stephenson MD; Cohn E; Salmon JE
Clin J Am Soc Nephrol; 2017 Jun; 12(6):940-946. PubMed ID: 28400421
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis.
Choi CB; Won S; Bae SC
Lupus; 2018 May; 27(6):1007-1011. PubMed ID: 29448881
[TBL] [Abstract][Full Text] [Related]
9. Immunosuppressive therapy withdrawal after remission achievement in patients with lupus nephritis.
Zen M; Fuzzi E; Loredo Martinez M; Depascale R; Fredi M; Gatto M; Larosa M; Saccon F; Iaccarino L; Doria A
Rheumatology (Oxford); 2022 Feb; 61(2):688-695. PubMed ID: 33909900
[TBL] [Abstract][Full Text] [Related]
10. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies.
Illei GG; Takada K; Parkin D; Austin HA; Crane M; Yarboro CH; Vaughan EM; Kuroiwa T; Danning CL; Pando J; Steinberg AD; Gourley MF; Klippel JH; Balow JE; Boumpas DT
Arthritis Rheum; 2002 Apr; 46(4):995-1002. PubMed ID: 11953977
[TBL] [Abstract][Full Text] [Related]
11. Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide.
Dall'Era M; Stone D; Levesque V; Cisternas M; Wofsy D
Arthritis Care Res (Hoboken); 2011 Mar; 63(3):351-7. PubMed ID: 21080348
[TBL] [Abstract][Full Text] [Related]
12. The influence of repeated flares in response to therapy and prognosis in lupus nephritis.
Perez-Arias AA; Márquez-Macedo SE; Pena-Vizcarra OR; Zavala-Miranda MF; Romero-Díaz J; Morales-Buenrostro LE; Mejía-Vilet JM
Nephrol Dial Transplant; 2023 Mar; 38(4):884-893. PubMed ID: 36318456
[TBL] [Abstract][Full Text] [Related]
13. Lupus nephritis flares.
Sidiropoulos PI; Kritikos HD; Boumpas DT
Lupus; 2005; 14(1):49-52. PubMed ID: 15732288
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors in diffuse proliferative lupus nephritis.
Abraham MA; Korula A; Jayakrishnan K; John GT; Thomas PP; Jacob CK
J Assoc Physicians India; 1999 Sep; 47(9):862-5. PubMed ID: 10778652
[TBL] [Abstract][Full Text] [Related]
15. Treatment outcomes in refractory lupus nephritis: Data from an observational study.
Gururani S; Devarasetti PK; Uppin M; Rajasekhar L
Lupus; 2021 Oct; 30(11):1725-1731. PubMed ID: 34304627
[TBL] [Abstract][Full Text] [Related]
16. Induction therapy with short-term high-dose intravenous cyclophosphamide followed by mycophenolate mofetil in proliferative lupus nephritis.
Arends S; Berden JH; Grootscholten C; Derksen RH; Berger SP; de Sévaux RG; Voskuyl AE; Bijl M;
Neth J Med; 2014 Nov; 72(9):481-90. PubMed ID: 25431394
[TBL] [Abstract][Full Text] [Related]
17. Morphological Indexes: Can They Predict Lupus Nephritis Outcomes? A Retrospective Study.
Navarro D; Ferreira AC; Viana H; Carvalho F; Nolasco F
Acta Med Port; 2019 Oct; 32(10):635-640. PubMed ID: 31625875
[TBL] [Abstract][Full Text] [Related]
18. Risk factors to predict the development of chronic kidney disease in patients with lupus nephritis.
Park DJ; Kang JH; Lee JW; Lee KE; Kim TJ; Park YW; Lee JS; Choi YD; Lee SS
Lupus; 2017 Oct; 26(11):1139-1148. PubMed ID: 28420060
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis.
Tamirou F; D'Cruz D; Sangle S; Remy P; Vasconcelos C; Fiehn C; Ayala Guttierez Mdel M; Gilboe IM; Tektonidou M; Blockmans D; Ravelingien I; le Guern V; Depresseux G; Guillevin L; Cervera R; Houssiau FA;
Ann Rheum Dis; 2016 Mar; 75(3):526-31. PubMed ID: 25757867
[TBL] [Abstract][Full Text] [Related]
20. Management of young patients with lupus nephritis using tacrolimus administered as a single daily dose.
Tanaka H; Oki E; Tsuruga K; Yashiro T; Hanada I; Ito E
Clin Nephrol; 2009 Dec; 72(6):430-6. PubMed ID: 19954719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
